tbuckley/cabot-search huggingface dataset:
Effect of Promoting High-Quality Staff Interactions on Fall Prevention in Nursing Homes
Authors: Cathleen S. Colón-Emeric, Kirsten Corazzini, Eleanor S. McConnell, Wei Pan, Mark Toles, Rasheeda Hall, Michael P. Cary, Melissa Batchelor-Murphy, Tracey Yap, Amber L. Anderson, Andrew Burd, Sathya Amarasekara, Ruth A. Anderson
Journal: JAMA Internal Medicine (2017)

New approaches are needed to enhance implementation of complex interventions for geriatric syndromes such as falls.To test whether a complexity science-based staff training intervention (CONNECT) promoting high-quality staff interactions improves the impact of an evidence-based falls quality improvement program (FALLS).Cluster-randomized trial in 24 nursing homes receiving either CONNECT followed by FALLS (intervention), or FALLS alone (control). Nursing home staff in all positions were asked to complete surveys at baseline, 3, 6, and 9 months. Medical records of residents with at least 1 fall in the 6-month pre- and postintervention windows (n = 1794) were abstracted for fall risk reduction measures, falls, and injurious falls.CONNECT taught staff to improve their connections with coworkers, increase information flow, and use cognitive diversity in problem solving. Intervention components included 2 classroom sessions, relationship mapping, and self-monitoring. FALLS provided instruction in the Agency for Healthcare Research and Quality's Falls Management Program.Primary outcomes were (1) mean number of fall risk reduction activities documented within 30 days of falls and (2) median fall rates among residents with at least 1 fall during the study period. In addition, validated scales measured staff communication quality, frequency, timeliness, and safety climate.Surveys were completed by 1545 staff members, representing 734 (37%) and 811 (44%) of eligible staff in intervention and control facilities, respectively; 511 (33%) respondents were hands-on care workers. Neither the CONNECT nor the FALLS-only facilities improved the mean count of fall risk reduction activities following FALLS (3.3 [1.6] vs 3.2 [1.5] of 10); furthermore, adjusted median recurrent fall rates did not differ between the groups (4.06 [interquartile range {IQR}, 2.03-8.11] vs 4.06 [IQR, 2.04-8.11] falls/resident/y). A modest improvement in staff communication measures was observed overall (mean, 0.03 [SE, 0.01] points on a 5-point scale; P = .03) and for communication timeliness (mean, 0.8 [SE, 0.03] points on a 5-point scale; P = .02). There was wide variation across facilities in intervention penetration.An intervention targeting gaps in staff communication and coordination did not improve the impact of a falls quality improvement program. New approaches to implementing evidence-based care for complex conditions in the nursing home are urgently needed.clinicaltrials.gov Identifier: NCT00636675.
NHS pay cap has been scrapped, says Hunt
Authors: Abi Rimmer
Journal: BMJ (2017)

The pay cap for NHS staff has been scrapped, the health secretary has said.

Speaking in the House of Commons on 10 October, Jeremy Hunt replied to a question about the effect of the NHS pay cap on staffing and waiting lists. He said, “The pay cap has been scrapped.”

At a conference in June, Hunt had said that he would put the case to the chancellor for lifting the current 1% pay cap.1 In September it was announced that the cap on public sector pay …
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Authors: Suriyan Ponnusamy, Christopher C. Coss, Thirumagal Thiyagarajan, Kate Watts, Dong-Jin Hwang, Yali He, Luke A. Selth, Iain J. McEwan, Charles B. Duke, Jayaprakash Pagadala, Geetika Singh, Robert W. Wake, Christopher Ledbetter, Wayne D. Tilley, Tudor Moldoveanu, James T. Dalton, Duane D. Miller, Ramesh Narayanan
Journal: Cancer Research (2017)

Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer. Cancer Res; 77(22); 6282-98. ©2017 AACR.
Clinical course in patients with stage III non-small cell lung cancer and interstitial lung disease treated with chemoradiotherapy: a retrospective analysis in a single institute
Authors: H. Kobayashi, T. Naito, K. Omae, S. Omori, K. Nakashima, K. Wakuda, A. Ono, H. Kenmotsu, H. Murakami, M. Endo, H. Harada, T. Takahashi
Journal: Annals of Oncology (2017)
New cell line models for the development of personalized therapy for high grade serous ovarian cancer
Authors: D. Castillo-Tong, I. Von Der Decken, S. Pfaffinger, A. Wolf, C. Kreuzinger, D. Smeets, B. Boeckx, D. Lambrechts, C. Singer, C. Grimm, A. Reinthaller, R. Horvat
Journal: Annals of Oncology (2017)
Thyroid hormone regulates hematopoiesis via the TR-KLF9 axis
Authors: Ying Zhang, Yuanyuan Xue, Chunwei Cao, Jiaojiao Huang, Qianlong Hong, Tang Hai, Qitao Jia, Xianlong Wang, Guosong Qin, Jing Yao, Xiao Wang, Qiantao Zheng, Rui Zhang, Yongshun Li, Ailing Luo, Nan Zhang, Guizhi Shi, Yanfang Wang, Hao Ying, Zhonghua Liu, Hongmei Wang, Anming Meng, Qi Zhou, Hong Wei, Feng Liu, Jianguo Zhao
Journal: Blood (2017)
Effects of Sublethal Doses of a Polysaccharide from &lt;italic&gt;Serratia Marcescens (Bacillus Prodigiosus)&lt;/italic&gt; on the Electrocardiogram, Blood Ascorbic Acid, and Non-Protein Nitrogen of the Dog&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: F. E. Franke, Dan Richert
Journal: JNCI Journal of the National Cancer Institute (1944)

Journal Article Effects of Sublethal Doses of a Polysaccharide from Serratia Marcescens (Bacillus Prodigiosus) on the Electrocardiogram, Blood Ascorbic Acid, and Non-Protein Nitrogen of the Dog Get access F. E. Franke, F. E. Franke assistant professor of physiology Department of Biochemistry, St. Louis University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar Dan Richert Dan Richert graduate fellow Department of Biochemistry, St. Louis University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 3, December 1944, Pages 179–183, https://doi.org/10.1093/jnci/5.3.179 Published: 01 December 1944
GW28-e1117 Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy on patients after implantation of multiple biodegradable polymer drug eluting coronary stents - a subgroup analysis from I-LOVE-IT 2 trial
Authors: Jing Qi, Yi Li, Heyang Wang, Jing Li, Yushan Chen, Yaling Han, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
La rage en Europe en 2005
Authors: H Bourhy, L Dacheux, C Strady, A Mailles
Journal: Eurosurveillance (2005)

En 2005, la rage est toujours presente en Europe. Son incidence chez l’homme reste limitee (moins de 5 cas par an) par l’application stricte de mesures de prophylaxie (traitements antirabiques) et par des mesures de controle veterinaire de la rage dans les populations animales sauvages et domestiques. Les principaux reservoirs animaux autochtones sont : le chien dans les pays d’Europe de l’est et aux frontieres avec le Moyen-Orient; le renard en Europe centrale et de l’est ; le chien viverrin en Europe du nord-est et les chauves-souris insectivores sur l’ensemble du territoire. Enfin, tous les ans des cas d’importation d’animaux enrages en provenance de zones d’enzootie sont recenses montrant la permeabilite de nos frontieres et l’absence de prise de conscience du risque rabique par les voyageurs. Ces importations menacent en permanence le statut indemne de rage des animaux non-volants des pays de l’ouest europeen et compliquent la decision therapeutique des medecins en l’absence d’information sur l’animal mordeur.
FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis
Authors: B. Pistilli, A. Lardy-Cleaud, E. Jacquet, S. Delaloge, P. Cottu, M. Debled, L. Vanlemmens, M. Leheurteur, F. Divanon, A. Gonçalves, C. Laurent, B. Coudert, E. Chamorey, L. Campion, M-A. Mouret-Reynier, M. Breton, T. Petit, G. Simon, C. Cailliot, T. Bachelot
Journal: Annals of Oncology (2017)
Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status
Authors: C. K. Anders, S. D. Hsu, C. R. Acharya, Y. Zhang, Y. Wang, J. A. Foekens, P. K. Marcom, J. R. Marks, J. Nevins, A. Potti, K. L. Blackwell
Journal: Journal of Clinical Oncology (2007)

522 Background: Breast cancer in young women [YW] has a poorer prognosis, is less likely hormone sensitive, and has yet to be defined as a unique biologic phenotype. The identification of molecular pathways unique to YW should enable refinement of treatment strategies. Methods: To optimize characterization of breast cancer arising in YW vs. older women [OW], we prospectively defined 2 age groups constituting pre- and post-menopausal women [YW = 45 yrs (median 40 yrs); OW = 65 yrs (median 71 yrs)]. Age groups were applied to 784 clinically-annotated microarray (Affymetrix) data. 411 patients (n = 200 = 45yrs; n = 211 = 65 yrs) were eligible. In addition to clinical parameters and differential gene expression analysis, genomic signatures of oncogenic pathway deregulation (Ras, E2F, β-catenin, PI3K, Myc, Src) and chemotherapeutic sensitivity were evaluated. Results: In the 2 age-defined tumor sets, there was no difference between ER or PR status by IHC (p = ns). Consistent with previous data sets, YW demonstrated higher IHC expression of ErbB2 (p = 0.037), higher grade tumors (p &lt; 0.0001), larger tumor size (p = 0.0002) and greater lymph node positivity (p = 0.045). Quantitative ER expression (mRNA) was lower (p &lt; 0.0001) among YW. In comparing deregulation of oncogenic pathways between age groups, a statistically higher probability of PI3K (p = 0.005) and Myc (p = 0.02) pathway deregulation was observed among YW. Importantly, hierarchical clustering revealed unique patterns of pathway deregulation. In YW, PI3K and β-catenin deregulation conferred a worse prognosis compared to those with Myc and Src deregulation (HR = 4.15; p = 0.008). In contrast, among OW, E2F deregulation with concurrent low probability of PI3K and Myc deregulation was associated with a poorer outcome (HR = 2.7; p = 0.006). Conclusion: Results of this large study demonstrate that breast cancer arising in YW represents a distinct biologic entity characterized by unique patterns of deregulated signaling pathways that are prognostic, independent of currently available clinical variables such as ER. Further data, including unique patterns of chemotherapeutic sensitivity as they relate to clinical parameters and oncogenic pathway status, will also be presented. [Table: see text]
Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial
Authors: L. Verlingue, D. Malka, A. Allorant, C. Massard, C. Ferté, L. Lacroix, E. Rouleau, N. Auger, J. Delahousse, R. Sun, T. de Baere, L. Tselikas, B. Ba, J-Y. Scoazec, S. Michiels, V. Boige, M. Ducreux, J-C. Soria, A. Hollebecque
Journal: Annals of Oncology (2017)
Surveillance de la listériose en Europe
Authors: H de Valk, C Jacquet, V Goulet, V Vaillant, A Perra, F Simon, J C Desenclos, P Martin
Journal: Eurosurveillance (2005)

Hormis l’impact economique et la menace inherente aux epidemies, la listeriose represente un probleme majeur de sante publique, en raison de son taux de letalite parmi les plus eleves de toutes les infections alimentaires, et de son potentiel epidemique important. L’evolution des methodes de production des aliments, de la distribution et du stockage a cree des conditions propices a la survenue d’epidemies touchant de nombreux pays. 
En 2002, une etude a ete menee afin d’evaluer le besoin et la faisabilite d’un reseau europeen sur les infections humaines a Listeria. Les donnees sur les systemes de surveillance et les methodes de laboratoire ont ete recueillies par le biais de deux questionnaires envoyes aux centres nationaux de surveillance des maladies transmissibles et aux laboratoires de reference des Listeria. Des systemes de surveillance de la listeriose etaient en place dans 16 des 17 pays interroges et 16 pays disposaient d’un laboratoire national de reference (LNR). Dans tous les pays, la definition de cas etait basee sur l’isolement de Listeria monocytogenes. Quatorze LNR realisent au moins une methode de typage des souches humaines. Au moins 13 pays procedaient deja, ou etaient en voie de le faire, a la caracterisation des isolats par electrophorese en gel pulse (PFGE) des souches humaines de L. monocytogenes selon un protocole normalise. Pour les participants, l’existence d’un reseau de surveillance europeen de la listeriose, en particulier pour la detection et l’investigation des epidemies, constituerait une veritable valeur ajoutee. Ils ont par ailleurs confirme la faisabilite d’un reseau de surveillance base sur les programmes nationaux existants.
Latent HIV-1 TAR Regulates 7SK-Responsive P-TEFb Target Genes and Targets Cellular Immune Responses in the Absence of Tat
Authors: Sebastian Eilebrecht, Bernd-Joachim Benecke, Arndt G. Benecke
Journal: Genomics Proteomics & Bioinformatics (2017)

Abstract The transactivating response element (TAR) structure of the nascent HIV-1 transcript is critically involved in the recruitment of inactive positive transcription elongation factor b (P-TEFb) to the promoter proximal paused RNA polymerase II. The viral transactivator Tat is responsible for subsequent P-TEFb activation in order to start efficient viral transcription elongation. In the absence of the viral transactivator of transcription (Tat), e.g., during latency or in early stages of HIV transcription, TAR mediates an interaction of P-TEFb with its inhibitor hexamethylene bis-acetamide-inducible protein 1 (HEXIM1), keeping P-TEFb in its inactive form. In this study, we address the function of HIV-1 TAR in the absence of Tat by analyzing consequences of HIV-1 TAR overexpression on host cellular gene expression. An RNA chimera consisting of Epstein-Barr virus-expressed RNA 2 (EBER2) and HIV-1 TAR was developed to assure robust overexpression of TAR in HEK293 cells. The overexpression results in differential expression of more than 800 human genes. A significant proportion of these genes is involved in the suppression of cellular immune responses, including a significant set of 7SK-responsive P-TEFb target genes. Our findings identify a novel role for HIV-1 TAR in the absence of Tat, involving the interference with host cellular immune responses by targeting 7SK RNA-mediated gene expression and P-TEFb inactivation.
Ferric Carboxymaltose to Treat Isovolemic Anemia
Authors: Zhang Yu, Tiangui Li
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis
Authors: K. Laktionov, A. Arzumanyan, L. Bolotina, V. Breder, N. Buevich, A. Danilova, E. Filippova, A. Kornietskaya, M. Kramchaninov, E. Kushniruk, D. Latipova, F. Moiseenko, T. Nikitina, S. Orlov, R. Orlova, S. Protsenko, K. Sarantseva, D. Stroyakovskiy, T. Ionova
Journal: Annals of Oncology (2017)
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Authors: Mario P. Colombo
Journal: Clinical Cancer Research (2017)

The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence. Clin Cancer Res; 23(20); 5999-6001. ©2017 AACRSee related article by Messenheimer et al., p. 6165.
Quantitative analysis of multiple elements in healthy and remodeled epithelium from human upper airway mucosa using nuclear microscopy
Authors: M.‐Q. Ren, Y.‐T. Zhou, H.‐X. Chen, T.‐Y. Li, S. K. Vajandar, T. Osipowicz, F. Watt, C.‐W. Li
Journal: Allergy (2017)

Elements are vital in airway mucosal physiology and pathology, but their distribution and levels in the mucosa remain unclear. This study uses the state-of-the-art nuclear microscopy facility to map and quantify multiple elements in the histology sections of nasal mucosa from patients with nasal polyps or inverted papilloma. Our results demonstrate that P and Ca are the most abundant elements in mucosa and their distinct difference between epithelial and subepithelial regions; more importantly, our results reveal decreased amounts of Cu and Zn in the remodeled epithelium as compared to the normal epithelium. These findings suggest that Cu and Zn may be beneficial targets to regulate aberrant epithelial remodeling in airway inflammation.
Viajantes que voltam a Suécia como sentinelas para comparar a incidência de doenças noutros países europeios - o esemplo das infecções por Campylobacter e Giardia
Authors: K Ekdahl, J Giesecke
Journal: Eurosurveillance (2004)

E difficil obter dados sobre a incidencia de doencas que sejam comparaveis entre paises. Por isso, comparamos o risco de infeccao de suecos que viajam a outros paises europeios.Utilizamos o numero de casos importados de infeccoes por Campylobacter e Giardia na base de dados nacional sueca de vigilância como numerador, e o numero de pessoas viajando a cada pais segundo uma base de dados commercial sobre viagens ao estrangeiro como denominador. O risco de infeccao em turistas tambem foi comparado com os dados de incidencia nacional para uma seleccao de paises.
Durante o periodo de sete anos de 1997 a 2003, foram diagnosticadas 14 829 infeccoes por Campylobacter e 1 112 por Giardia em Suecos voltando de um pais europeio. Em uma base de dados de viagens ha informacoes sobre 14 519 viagens de estadias de uma noite a um destes paises no mesmo periodo. O risco de infeccao por Campylobacter era superior a 100 por 100 000 para viagens a Portugal e Turquia, mas so era de 1 para a Finlândia. O risco mais alto de giardasis era em Rusia (50 por 100 000). A sub-notificacao das infeccoes por Campylobacter e substancial em muitos paises europeus. 
Em conclusao, o risco de infeccao por Campylobacter e Giardia varia de 1 a 100 segundo o pais de Europa. Turistas de volta a Suecia considerados como uma populacao sentinela constituem um instrumento util para a estimacao dessas variacoes. Existem diferencas importantes - e inexplicadas - entre o risco para os viajantes e os dados de incidencia nacional.
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
Authors: Andrzej J. Jakubowiak, Ajai Chari, Sagar Lonial, Brendan M. Weiss, Raymond L. Comenzo, Kaida Wu, Nushmia Z. Khokhar, Jianping Wang, Parul Doshi, Saad Zafar Usmani
Journal: Journal of Clinical Oncology (2017)

8000 Background: DARA in combination with established standard of care regimens prolongs PFS, deepens responses, and demonstrates a favorable safety profile in relapsed or refractory multiple myeloma (MM). The tolerability and efficacy of DARA-KRd in newly diagnosed MM pts was examined. Methods: Newly diagnosed pts regardless of transplantation eligibility were enrolled. Pts received DARA 16 mg/kg QW for Cycles 1-2, Q2W for Cycles 3-6, and Q4W thereafter. All pts received the 1st dose of DARA split over 2 days. Carfilzomib (K) was administered on Days 1, 8 and 15 of each 28-day cycle (20 mg/m 2 on C1D1, 36 or 70 mg/m 2 subsequently based on tolerability of first dose) for ≤13 cycles or elective discontinuation for ASCT. Lenalidomide 25 mg was given on Days 1-21 and dexamethasone 20-40 mg per week. The primary endpoint was tolerability. Results: Twenty-two pts (median [range] age, 60 [34-74] y) were enrolled and received a median of 8 (1-10) treatment cycles. Nineteen pts escalated K dose to 70 mg/m 2 by C1D15. Median (range) duration of follow-up was 7.4 (4.0-9.3) months. Six (27%) pts discontinued treatment (1 AE [pulmonary embolism]; 1 PD; 4 other [ASCT]). Serious AEs occurred in 46% of pts, and 14% were possibly related to DARA; 18 (82%) experienced a grade 3/4 TEAE. The most common grade 3/4 TEAEs (&gt;10%) were lymphopenia (50%) and neutropenia (23%); 1 (5%) cardiac grade 3 TEAE was observed (congestive heart failure) which resolved; pt quickly resumed study treatment with reduced K dose. No grade 5 TEAE was reported. All DARA-associated infusion reactions (27% of pts) were grade ≤2. Treatment with DARA-KRd yielded an ORR (≥partial response) of 100% (5% complete response, 86% ≥very good partial response) in 21 response-evaluable pts. The 6-month PFS rate was 100%. Conclusions: The addition of DARA to KRd was well tolerated; the overall safety profile was consistent with that previously reported for KRd, with no additional toxicity observed with the addition of DARA. Deep and durable responses were observed. These data support further investigation of DARA-KRd as a frontline treatment regimen. Updated data will be presented based on longer follow up. Clinical trial information: NCT01998971.